BSC1600

BSC1600 is a preclinical-stage therapeutic candidate being developed by BiSiChem. It utilizes a lipid nanoparticle (LNP) delivery system to target Transforming Growth Factor-beta (TGF-β). TGF-β is a multifunctional cytokine that plays a critical role in regulating cell growth, differentiation, and immune responses. Dysregulation of the TGF-β pathway is a hallmark of various pathological conditions, including cancer progression and tissue fibrosis. By employing LNPs, BSC1600 likely aims to deliver a genetic payload (such as siRNA or mRNA) to specifically inhibit or modulate TGF-β signaling, potentially overcoming the limitations of systemic small-molecule inhibitors and improving tissue-specific delivery.